TEMOZOLOMIDE VIATRIS 5 mg

DRUG3 trials

Sponsors

Replimune Inc., Institut De Recherches Internationales Servier IRIS, Institut Gustave Roussy

Conditions

Advanced MelanomaIDH1-mutant GliomaIDH2-mutant Gliomapediatric cancer

Phase 1

AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

RecruitingCTIS2024-514791-40-00

Institut Gustave Roussypediatric cancer

Start: 2016-08-03Target: 398Updated: 2025-10-06

A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma

Active, not recruitingCTIS2024-513738-39-00

Institut De Recherches Internationales Servier IRISIDH1-mutant Glioma, IDH2-mutant Glioma

Start: 2025-03-18Target: 17Updated: 2025-12-18

Phase 3

A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician’s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen [IGNYTE-3]

RecruitingCTIS2023-508612-29-00

Replimune Inc.Advanced Melanoma

Start: 2025-11-07Target: 193Updated: 2025-11-04